Introduction
============

The ability of neurons to remodel and modify their synaptic connections is a fundamental requirement for higher brain functions such as learning and memory. Defects in this form of synaptic plasticity have been associated with the pathophysiological manifestations of many neurodegenerative diseases and mental illnesses ([@bib40]; [@bib15]). Increasing evidence suggests that signaling cascades initiated by secreted molecules such as bone morphogenic protein (BMP), Wnt/wingless (Wg), and FGF are essential for the coordinated assembly of the synapse ([@bib21]; [@bib20]; [@bib34]; [@bib11]). Despite recent progress, we know little about how these signaling cascades are modulated in neurons to ensure appropriate synaptic growth. In this study, we describe a mechanism by which BMP signaling is modulated through interaction between the Nemo (Nmo) kinase and the BMP transcription factor Mad in *Drosophila melanogaster* larval motor neurons.

In vertebrates, BMP signaling has been shown to control different aspects of neuronal development both in the spinal cord and the brain ([@bib17]). The role for BMP signaling in regulating synaptic growth has been well characterized at the *Drosophila* larval neuromuscular junction (NMJ). Based on the current evidence, the BMP ligand Glass Bottom Boat provides a retrograde signal from the muscle back to the nerve terminal; this signal is processed by a receptor complex comprised of the type I BMP receptors Thickveins (Tkv) and Saxophone and the type II BMP receptor Wishful thinking. Receptor activation then leads to an increase in the phosphorylation of the R-Smad Mad at the NMJ terminals followed by nuclear translocation of phosphorylated Mad (p-Mad) through its interaction with the co-Smad Medea. Mutations of the members of this cascade lead to a drastic reduction in the number of synaptic boutons and the amount of neurotransmitter release at the NMJ ([@bib1]; [@bib18]; [@bib20], [@bib19]).

A large body of research has provided evidence for Smad regulation by several posttranslational mechanisms such as ubiquitination, phosphorylation, and sumoylation, to name a few ([@bib25]); however, we know little about how Smads are regulated in neurons. In a forward genetic suppressor screen, we have identified Nmo kinase as a regulator of synaptic growth at the *Drosophila* larval NMJ. Our findings provide evidence that the normal function of Mad depends on its phosphorylation by Nmo. Interaction between Nmo and Mad provides a mechanism for the modulation of BMP signaling in motor neurons and thus the structural growth and function of synaptic boutons at the NMJ.

Results
=======

Nmo is required in motor neurons for normal synaptic growth at the larval NMJ
-----------------------------------------------------------------------------

Loss-of-function mutations in the E3 ubiquitin ligase *highwire* (*hiw*) lead to extensive synaptic expansion at the NMJ ([@bib35]). We reasoned that if a candidate gene could dominantly suppress the synaptic expansion in *hiw* mutants, it would likely be involved in the regulation of synaptic growth. To search for such candidate genes, we tested whether inclusion of a chromosome containing deletions (deficiency chromosome) could dominantly suppress the synaptic expansion in *hiw* mutants. We focused on chromosomal deficiency lines available on the left arm of the third chromosome and found that *hiw* larvae with one copy of *Df(3L)pbl-X1* showed significantly less synaptic expansion compared with *hiw* larvae. We tested genetic interaction with smaller overlapping deficiencies and were able to identify the gene *nmo* ([@bib5]) as the locus responsible (see Materials and methods; [Fig. S1](http://www.jcb.org/cgi/content/full/jcb.200809127/DC1)).

Nmo is the founding member of the evolutionarily conserved Nmo-like kinase family of serine/threonine kinases ([@bib5]). Nmo was first identified as a regulator of epithelial planar cell polarity during eye development ([@bib5]). Moreover, Nmo has been implicated in several developmental processes, including the regulation of patterning and imaginal disc development ([@bib38]; [@bib33]), but its function in the nervous system has not been characterized. To study the role of Nmo in synaptic growth, we examined NMJs from wandering third instar larvae using antibodies against pre- and postsynaptic markers. NMJs undergo rapid structural and functional growth in the few days of larval development; during this time, the number of synaptic boutons increases several fold to keep up with the growing muscle ([@bib26]; [@bib13]; [@bib8]). This coordinated growth appeared defective in *nmo* mutants ([Fig. 1](#fig1){ref-type="fig"}); however, we did not observe any detectable abnormalities in the pattern of innervation of the body wall muscles in *nmo* mutant larvae (not depicted), suggesting that motor neuronal pathfinding and initial target recognition are not affected. A feature of wild-type NMJs is the presence of chains of synaptic boutons organized like beads on a string ([@bib4]; [@bib39]) forming synaptic branches that contain as many as 20 boutons ([Fig. 1 A](#fig1){ref-type="fig"}). However, in *nmo* mutants, this feature was severely affected, as most NMJs lacked branches containing more than five boutons ([Fig. 1, B and C](#fig1){ref-type="fig"}). Different genetically null alleles of *nmo* in trans-allelic and homozygous combinations showed a strong reduction in the number of type I synaptic boutons (86.5 ± 3.0 and 54.5 ± 3.6 for wild type and *nmo^P^*/*Df(3L)Exel6279*, respectively; *n* = 20; P \< 0.001) at muscles 6 and 7. Type I glutamatergic boutons have been divided into two categories, big (type Ib) and small (type Is), based on their size as well as on the intensity of their Discs large (Dlg) signal ([Fig. 1 A](#fig1){ref-type="fig"}, arrowhead and arrow; [@bib4]). We found that both Ib and Is boutons were reduced in *nmo* mutants. We observed a similar reduction in the number of boutons at muscle 4 NMJs (58.9 ± 2.6 and 35.3 ± 3.3 for wild type and *nmo^P^*/*Df(3L)Exel6279*, respectively; *n* = 20; P \< 0.001). To accurately reflect the role of Nmo in coordinated synaptic growth, we normalized the total number of boutons at every NMJ to the corresponding muscle surface area (MSA). This approach avoids any biases that might arise as the result of variations in the muscle size among different larvae. Our quantifications showed that in *nmo* mutants, the number of boutons per MSA was reduced by ∼40% ([Fig. 1 D](#fig1){ref-type="fig"}).

![**Nmo is required for normal synaptic growth at the NMJ.** (A) Wild-type (wt) third instar larval NMJ synapses at muscles 6 and 7 in the third abdominal segment double stained with anti-Dlg (red) and anti-HRP (green). The arrow indicates a type Is bouton; the arrowhead indicates a type Ib bouton. (B and C) NMJs at muscles 6 and 7 in two different *nmo* mutant combinations. (D) Bar graph showing the normalized total number of boutons/MSA in wild type and in three *nmo* mutant combinations (*n* ≥ 20; mean ± SEM; \*\*\*, P \< 0.001). Bar, 10 µm.](JCB_200809127_RGB_Fig1){#fig1}

In situ hybridization experiments have previously demonstrated an enrichment of *nmo* transcript in the ventral nerve cord and in the brain at late embryonic stages ([@bib33]). To further test whether the *nmo* transcript is present in motor neurons, we took advantage of a *nmo* LacZ enhancer trap fly (*nmo^P^*); expression of β-galactosidase (β-gal) from *nmo^P^* closely resembles the endogenous expression pattern of *nmo* ([@bib5]; [@bib38]; [@bib36]). We were able to detect a specific anti--β-gal signal in a subset of neurons, including all motor neurons, in the ventral nerve cord. To confirm the identity of the β-gal--positive neurons in *nmo^P^*, we costained the ventral nerve cord with an antibody against p-Mad; p-Mad normally accumulates in the nuclei of motor neurons ([@bib18]; [@bib20]). We found that all p-Mad--positive motor neurons were also positive for β-gal ([Fig. 2, A--F](#fig2){ref-type="fig"}). To further assess the expression pattern of the *nmo* transcript, we generated larvae that contained one copy of *nmo^P^* enhancer trap while expressing upstream activating sequence (UAS)--mCD8-GFP in all motor neurons using motor neuronal Gal4 driver BG380; double staining of ventral nerve cords with anti-GFP and anti--β-gal antibodies revealed that the *nmo* transcript is not exclusively expressed in motor neurons (unpublished data). Next, we wished to examine the pattern of expression of Nmo protein; however, the available Nmo antibodies failed to detect a specific signal. Thus, we turned to a GFP-Nmo fusion transgene (UAS-GFP-Nmo; [@bib9]) to investigate whether Nmo can localize at synaptic sites. We detected GFP signal at all NMJ synapses after overexpression of UAS-GFP-Nmo using BG380-Gal4 ([Fig. 2, G and H](#fig2){ref-type="fig"}), suggesting that Nmo protein can localize to the NMJ. In addition, we found that GFP-Nmo was evenly distributed in motor neuronal cell bodies and nuclei without any apparent concentration in any compartments ([Fig. 2 I](#fig2){ref-type="fig"}). We did not find a significant change in the number of boutons per MSA in response to Nmo overexpression ([Fig. 2 J](#fig2){ref-type="fig"}).

![**Nmo is required in motor neurons for normal synaptic growth at the NMJ.** (A) β-gal staining in the ventral nerve cord of larvae heterozygous for *nmo^P^*. (B) β-gal--positive neurons are also p-Mad positive. (C) Merged image of A and B; p-Mad is shown in green, and β-gal is shown in red. (D--F) Graphic representation of signal intensity in individual motor neurons corresponding to A--C. (G) The transgenic GFP-Nmo fusion protein localizes to the presynaptic domain of the NMJ when expressed in motor neurons. (H) The same NMJ is stained with an anti-HRP antibody, and the merged image is shown. (I) Overexpressed GFP-Nmo also localizes to motor neuronal cell bodies. (J) Bar graph showing the normalized total number of type I boutons per MSA in wild type (wt) and larvae overexpressing GFP-Nmo in motor neurons (*n* ≥ 20; mean ± SEM). (K--M) Larval NMJ synapses at muscle 4 double stained with anti-Dlg (red) and anti-HRP (green) antibodies in wild type (K), *nmo* mutant (L), and *nmo* mutant overexpressing GFP-Nmo in motor neurons (M). (N--Q) Larval NMJ synapses at muscles 6 and 7 in wild type (N), *nmo* mutant (O), *nmo* mutant overexpressing Nmo in motor neurons (P), or *nmo* mutant overexpressing Nmo in muscles (Q). (R) Bar graph showing the normalized total number of type I boutons per MSA in the genotypes shown in N--Q (*n* = 20; mean ± SEM; \*\*\*, P \< 0.001). Bars, 10 µm.](JCB_200809127_RGB_Fig2){#fig2}

To determine whether Nmo is required pre- or postsynaptically, we performed genetic rescue experiments in *nmo* mutant larvae. We found that motor neuronal overexpression of UAS-Nmo or UAS-GFP-Nmo but not muscle overexpression was able to rescue the reduction in the number of boutons per MSA in *nmo* mutants (NMJs at muscles 6 and 7, [Fig. 2, N--R](#fig2){ref-type="fig"}; NMJs at muscle 4, [Fig. 2 K--M](#fig2){ref-type="fig"}). The presence of *nmo* transcription in motor neurons, the ability of Nmo protein to localize to presynaptic structures, and the rescue of synaptic defects in *nmo* mutants by presynaptic Nmo together led us to conclude that Nmo is required in presynaptic motor neurons for normal growth of NMJ synaptic structures.

Nmo binds Mad and is required for normal accumulation of p-Mad in motor neurons
-------------------------------------------------------------------------------

Our findings indicated that genetic reduction of *nmo* in motor neurons can significantly suppress NMJ overexpansion in *hiw* mutants (Fig. S1, A--D). Previously, it has been shown that loss of Wallenda (Wnd), a MAPK kinase kinase, can lead to suppression of the *hiw* loss-of-function phenotype ([@bib6]). Wnd levels are up-regulated in the central nervous system of *hiw* mutant larvae ([@bib6]). Therefore, we tested whether Wnd protein levels in the central nervous system are affected as a consequence of loss of *nmo*. We found no detectable changes in the levels of anti-Wnd antibody signal associated with loss of *nmo* (Fig. S1, E--I). Synaptic overexpansion in *hiw* mutants is also dependent on normal BMP signaling in motor neurons ([@bib19]). Moreover, it has recently been demonstrated that Nmo can interact with and phosphorylate the BMP transcription factor Mad in vitro ([@bib37]). Therefore, we examined whether Nmo participates in the regulation of BMP signaling in motor neurons. As a first step, we set out to test whether the normal accumulation of p-Mad is affected in *nmo* mutants. p-Mad accumulation at the terminals and in the nuclei of motor neurons is an indicator of retrograde BMP signaling at the NMJ ([@bib18]; [@bib20]). Using an anti--p-Mad antibody, we were able to detect p-Mad in the nuclei of motor neurons in wild-type and *nmo* mutants ([Fig. 3, A--F](#fig3){ref-type="fig"}); however, our quantification of the fluorescence intensity associated with the p-Mad signal in the ventral nerve cord showed an ∼30% (P \< 0.001) decrease in *nmo* mutants compared with wild type ([Fig. 3, A--F and J](#fig3){ref-type="fig"}). In contrast, we found a strong increase in the p-Mad signal at the NMJs. We quantified this increase in two ways. First, we measured the intensity of the signal per individual p-Mad punctum between the two groups and found that *nmo* mutants show a 25% increase compared with wild type (P \< 0.001; [Fig. 3 K--P and T](#fig3){ref-type="fig"}). Second, we measured the total amount of fluorescence per synaptic area for p-Mad and normalized it to the amount of fluorescence for Fas2 in the same synaptic area between the two groups; using this measurement, we found that p-Mad signal was increased by 35% in *nmo* mutants compared with wild type (*n* = 16; P \< 0.001). The p-Mad signal in *nmo* mutants was restored to normal levels when we provided Nmo in motor neurons ([Fig. 3, G--J and Q--T](#fig3){ref-type="fig"}). To rule out the possibility that the abnormal accumulation of p-Mad is merely caused by a general defect in axonal transport in *nmo* mutants, we examined motor axons in *nmo* and wild-type larvae after overexpression of UAS-Mito-GFP ([@bib7]). UAS-Mito-GFP is a marker for mitochondria and can be used in live larvae to assess retrograde and anterograde axonal transport ([@bib24]). We did not find any abnormalities or apparent differences in the accumulation of Mito-GFP puncta in *nmo* mutant larvae ([Fig. S2, A--E](http://www.jcb.org/cgi/content/full/jcb.200809127/DC1)). Similarly, we did not observe any apparent differences in the accumulation of synaptotagmin (Syt; Fig. S2, F--N), Bruchpilot, or Fas2 in axons of *nmo* mutant larvae (not depicted). These results suggest that Nmo specifically influences p-Mad distribution and accumulation in motor neurons.

![**Nmo is required for the normal accumulation of p-Mad in motor neurons, and it colocalizes and coimmunoprecipitates with Mad.** (A--I) Motor neuron nuclei in third instar larval ventral nerve cords double stained with DAPI (red) and p-Mad (green) in wild-type (wt; A--C), *nmo* mutant (D--F), and *nmo* mutant larva overexpressing UAS-Nmo in motor neurons (G--I). (K--S) Terminal boutons at muscle 4 NMJs double stained with anti-Fas2 (red) and anti--p-Mad (green) antibodies in wild-type (K--M), *nmo* mutant (N--P), and *nmo* mutant larva overexpressing the Nmo transgene in motor neurons (Q--S). (J and T) Box plots showing the total fluorescence corresponding to the p-Mad signal in motor neuron nuclei (J) or the mean intensity of p-Mad puncta at the NMJ (T) for the aforementioned genotypes. *n* ≥ 80 motor neurons in J, and *n* ≥ 175 synaptic boutons in T from at least 10 larvae (mean ± SEM; \*\*\*, P \< 0.001). (U--W) Synaptic boutons stained with anti-GFP (green; U) and anti-Myc (red; V) and the merged image (W) are shown. Insets show partial 3D reconstructions of a synaptic bouton. (X) Western blots showing the presence of GFP-Nmo after immunoprecipitation (IP) of Myc-Mad using an anti-Myc antibody. VNC, ventral nerve cord. Bars, 10 µm.](JCB_200809127R_RGB_Fig3){#fig3}

Nmo and Mad have been shown to interact in vitro ([@bib37]); therefore, we wished to verify whether Nmo and Mad also interact in larval tissue. In the absence of reliable anti-Mad and anti-Nmo antibodies, we decided to use tagged transgenes of Mad and Nmo. For this, we generated an Myc-tagged Mad transgene and coexpressed it together with GFP-Nmo in all motor neurons. We found a significant overlap between the signals associated with Myc-Mad and GFP-Nmo at the NMJ ([Fig. 3, U--W](#fig3){ref-type="fig"}). In addition, we used Myc-Mad together with GFP-Nmo in coimmunoprecipitation experiments. We found that, in preparations which were immunoprecipitated with the anti-Myc antibody, we could also detect the presence of Nmo using an anti-GFP antibody ([Fig. 3 X](#fig3){ref-type="fig"}), suggesting that Mad and Nmo can be present in the same protein complex.

Phosphorylation of Mad by Nmo is required for the normal function of Mad
------------------------------------------------------------------------

Next, we investigated whether phosphorylation of Mad by Nmo is required for Mad\'s normal physiological function in motor neurons. Nmo can specifically phosphorylate Mad in vitro at serine 25, a site distinct from the phosphorylation site by type I BMP receptors at the C terminus of Mad ([@bib32]; [@bib37]). If Nmo indeed phosphorylates Mad in vivo, and if this phosphorylation is physiologically relevant, its loss should affect the ability of Mad to function normally in the nervous system. We tested this hypothesis by performing rescue experiments in *Mad* mutants using a Mad transgene that cannot be phosphorylated by Nmo (UAS-Myc-Mad^S25A^). Neuronal overexpression of UAS-Myc-Mad was able to restore the number of boutons per MSA in *Mad* mutants; however, UAS-Myc-Mad^S25A^ rescued *Mad* mutants only partially ([Fig. 4, A--E](#fig4){ref-type="fig"}). We verified that Myc-Mad and Myc-Mad^S25A^ showed similar levels of expression in motor neurons by Western blotting ([Fig. S3](http://www.jcb.org/cgi/content/full/jcb.200809127/DC1)). Protein levels were quantified by densitometry, and comparable protein levels were found.

![**Nmo phosphorylation of Mad is required for its normal function and distribution in motor neurons.** (A--D) Larval NMJs at muscle 4 double stained with anti-Dlg (red) and anti-HRP (green) in wild type (wt; A), homozygous *Mad^237^* (B), and *Mad^237^* rescued by UAS-Myc-Mad^S25A^ (C) or UAS-Myc-Mad (D). (E) Bar graph showing the normalized total number of boutons per MSA in the genotypes shown in A--D (*n* ≥ 14; mean ± SEM; \*\*, P \< 0.01; \*\*\*, P \< 0.001). (F--K) Ventral nerve cords (F--H) and NMJs (I--K) stained with anti-Myc in wild-type larvae overexpressing UAS-Myc-Mad (F and I) or UAS-Myc-Mad^S25A^ (G and J) and *nmo* mutant larvae overexpressing UAS-Myc-Mad (H and K). (L) Bar graph showing the normalized index of mean fluorescence intensity for the Myc signal at the NMJ versus motor neuron nuclei for Myc-Mad, Myc-Mad^S25A^, and Myc-Mad in *nmo* mutants (*n* = 16 larvae and two NMJs per larva; mean ± SEM; \*, P \< 0.05). (M) Bar graph showing the nuclear versus cytoplasmic Myc signal from wild-type larvae overexpressing Myc-Mad or Myc-Mad^S25A^ and from *nmo* mutants overexpressing Myc-Mad using BG380-Gal4 (*n* ≥ 40 from five larvae; mean ± SEM). (N--U) Terminal boutons at muscle 4 NMJs double stained with anti--p-Mad (green) and anti-HRP (red) in wild type (N and O), *nmo* mutant (*nmo^DB24^*/*Df(3L)Exel6279*; P and Q), *nmo* mutant larva overexpressing GFP-Nmo transgene in motor neurons (R and S), and *nmo* mutant larva overexpressing GFP-Nmo^K69M^ in motor neurons (T and U). (V) Bar graph showing p-Mad fluorescence relative to HRP for the genotypes in N--U (*n* = 8 larvae; mean ± SEM; \*, P \< 0.05; \*\*, P \< 0.01). (W) Bar graph showing p-Mad fluorescence intensity in the nuclei of dorsal motor neurons for the genotypes in N--U (*n* \> 200 motor neurons from 8--10 larvae; mean ± SEM; \*, P \< 0.05; \*\*, P \< 0.01). Bars, 10 µm.](JCB_200809127_RGB_Fig4){#fig4}

We next analyzed the localization of these two transgenes using immunohistochemistry in larval preparations. We found that both Myc-Mad and Myc-Mad^S25A^ were detectable in motor neuronal nuclei and at synaptic terminals ([Fig. 4, F--K](#fig4){ref-type="fig"}). However, closer analysis of the Myc signal revealed a proportional increase at the NMJ versus motor neuronal nuclei for Myc-Mad^S25A^ compared with Myc-Mad. For this, we generated an index representing the Myc signal at the NMJ in relation to the Myc signal in the nuclei of motor neurons for each larva. Using confocal projections, we measured the amount of fluorescence signal at the NMJ per area and divided that by the amount of fluorescence per area obtained from motor neuronal nuclei for each larva (see Materials and methods). On average, larvae expressing Myc-Mad^S25A^ showed a \>50% increase in this index compared with larvae that expressed Myc-Mad (P \< 0.05; *n* = 12; [Fig. 4 L](#fig4){ref-type="fig"}), which is reminiscent of the distribution of p-Mad in *nmo* mutants ([Fig. 3](#fig3){ref-type="fig"}). Then, we tested the effect of loss of *nmo* on this distribution index and found that loss of *nmo* led to an ∼45% increase in the index with a p-value of 0.0504 (*n* = 12; [Fig. 4 L](#fig4){ref-type="fig"}).

Because Nmo has been shown to induce nuclear export of Mad in heterologous cells, we wished to examine the role of Nmo in inducing nuclear export of Mad in motor neurons. For this, we quantified the amount of fluorescence in the nuclei of motor neurons expressing Myc-Mad and divided that by the amount of fluorescence obtained from the entire cell body in each motor neuron in the presence or absence of *nmo*; we found no significant difference between the nuclear fraction of Myc signal between wild-type and *nmo* larvae ([Fig. 4 M](#fig4){ref-type="fig"}). Similarly, the nuclear fraction of Myc signal in larvae overexpressing UAS-Myc-Mad^S25A^ was not different from that of wild-type UAS-Myc-Mad ([Fig. 4 M](#fig4){ref-type="fig"}). These findings are consistent with our earlier observations of p-Mad distribution in *nmo* mutant larvae and suggest that phosphorylation of Mad at serine 25 by Nmo is not essential for normal nuclear export of Mad in motor neurons. Nevertheless, these results do not rule out the possibility that Nmo can induce nuclear export of Mad when overexpressed, as observed previously by [@bib37].

Finally, we tested the importance of Nmo\'s kinase activity in the regulation of p-Mad accumulation and distribution in motor neurons. We generated a transgenic Nmo carrying a point mutation in a critical residue in the catalytic domain of Nmo, UAS-GFP-Nmo^K69M^. When overexpressed in motor neurons, GFP-Nmo^K69M^ localized to NMJ terminals in a manner similar to GFP-Nmo but caused a mild reduction in the number of boutons (Fig. S4, A--E), suggesting that it perhaps acts as a dominant negative. We tested whether Nmo^K69M^ can rescue the abnormal p-Mad distribution in motor neurons in *nmo* mutants, and, not surprisingly, we found that it failed to restore p-Mad to normal levels ([Fig. 4, N--W](#fig4){ref-type="fig"}; and Fig. S4, F--I). These findings are consistent with a model in which Nmo phosphorylation of Mad at serine 25 influences the distribution and accumulation of Mad in motor neurons and is required for Mad\'s normal function in promoting synaptic growth.

*nmo* and *Mad* genetically interact
------------------------------------

The effect of *nmo* loss-of-function on p-Mad distribution as well as the biochemical interaction between Mad and Nmo prompted us to test whether *nmo* and *Mad* could genetically interact. To test this possibility, we asked whether *Mad* and *nmo* would show trans-heterozygous genetic interaction. We found that synaptic structures showed significant abnormalities when one copy of *nmo* and one copy of *Mad* were genetically removed ([Fig. 5, A--E](#fig5){ref-type="fig"}), whereas loss of one copy of either was not significantly different from wild type. The number of type I boutons per MSA in *Mad*^+/−^;*nmo*^+/−^ trans-heterozygous larvae was reduced by \>30% compared with heterozygous control larvae ([Fig. 5 E](#fig5){ref-type="fig"}). This trans-heterozygous interaction was rescued by neuronal overexpression of Nmo in different trans-allelic combinations ([Fig. 5 E](#fig5){ref-type="fig"}). To further examine the functional interaction between Mad and Nmo, we tested synaptic structures in *Mad;nmo* double mutants. We found that the number of boutons per MSA in these larvae was statistically similar to that in *Mad* mutants alone but significantly lower from that in *nmo* mutants ([Fig. 5, F--J](#fig5){ref-type="fig"}). These results suggest that Mad and Nmo most likely function together in the same pathway to control synaptic growth at the NMJ. These results also raise the possibility that an increase in BMP signaling may be capable of restoring synaptic defects in *nmo* mutants. We tested this hypothesis by overexpressing either UAS-Myc-Mad or a constitutively active form of the type I BMP receptor Tkv (UAS-Tkv-act; [@bib12]) in motor neurons in *nmo* mutant larvae. UAS-Tkv-act has been shown to increase the amount of p-Mad in the nuclei of motor neurons ([@bib6]) without affecting the number of boutons at the NMJ ([@bib19]). Overexpression of either UAS-Myc-Mad or UAS-Tkv-act did not affect the number of boutons per MSA ([Fig. 5 K](#fig5){ref-type="fig"}). Although overexpression of Mad did not significantly increase the number of boutons in *nmo* mutant larvae, overexpression of UAS-Tkv-act did so significantly (60.77 ± 2.6 for BG380;*nmo^−/−^* compared with 75.67 ± 6.6 for BG380;UAS-Tkv-act/+;*nmo^−/−^*; *n* = 12; P = 0.018; [Fig. 5 K](#fig5){ref-type="fig"} and [Fig. S5, A--D](http://www.jcb.org/cgi/content/full/jcb.200809127/DC1)). These results further support a model in which Nmo regulates synaptic structural growth at the NMJ via its interaction with BMP signaling in motor neurons.

![***nmo* and *Mad* genetically interact.** (A--D) NMJs at muscle 4 double stained with anti-Dlg (red) and anti-HRP (green) in wild type (wt; A), heterozygous *nmo* mutants (B), heterozygous *Mad* mutants (C), and trans-heterozygous *Mad^−/+^;nmo^−/+^* mutants (D). (E) Bar graph showing the normalized total number of boutons/MSA in wild type, heterozygous *nmo* and *Mad* mutants, trans-heterozygous *Mad;nmo* mutants, and trans-heterozygous *Mad;nmo* mutants overexpressing Nmo in motor neurons (*n* ≥ 12; mean ± SEM; \*\*\*, P \< 0.001). (F--I) NMJs at muscle 4 double stained with anti-Dlg (red) and anti-HRP (green) in wild type (F), homozygous *nmo* mutants (G), homozygous *Mad* mutants (H), and *Mad;nmo* double mutants (I). (J) Bar graph showing the normalized total number of boutons/MSA for the genotypes in F--I (*n* ≥ 20; mean ± SEM; \*\*\*, P \< 0.001). (K) Bar graph showing the normalized total number of boutons/MSA in wild-type and *nmo* mutant larvae as well as in wild-type or *nmo* mutant larvae overexpressing UAS-Myc-Mad or UAS-Tkv-act using BG380-Gal4 (*n* ≥ 10; mean ± SEM; \*, P \< 0.05; \*\*\*, P \< 0.001). *Df* corresponds to *Df(3L)Exel6279*. Bars, 10 µm.](JCB_200809127R_RGB_Fig5){#fig5}

Nmo overexpression negatively regulates synaptic release
--------------------------------------------------------

Loss of BMP signaling has a profound effect on neurotransmitter release at the NMJ ([@bib1]; [@bib19]). Based on our results, we predicted that loss of *nmo* would mimic partial loss of BMP signaling, leading to a decrease in quantal release. Using a standard two-electrode voltage-clamp technique, we evaluated electrophysiological properties of *nmo* mutant larvae by measuring postsynaptic evoked junctional currents (EJCs) as well as miniature EJCs (mEJCs). To our surprise, quantal content in *nmo* mutants appeared normal. Although EJCs, quantal content, and mEJC frequency showed an increase on average compared with wild type, we did not find any statistically significant difference between the two groups (quantal content, 25.92 ± 4.7 for control vs. 29.23 ± 3.25 for *nmo*; *n* = 12; P = 0.56; EJC, P = 0.25; frequency of mEJC, P = 0.16; [Fig. 6, A, C, and G](#fig6){ref-type="fig"}). In contrast, *Mad* mutants, as reported previously ([@bib19]), showed a severe reduction in quantal release compared with wild type ([Fig. 6, B and G](#fig6){ref-type="fig"}). These results suggested that the normal function of Mad in the regulation of synaptic strength is not dependent on Nmo. In support of this conclusion, both UAS-Myc-Mad and UAS-Myc-Mad^S25A^ were capable of restoring normal synaptic function in *Mad* mutant larvae ([Fig. 6, D, E, and G](#fig6){ref-type="fig"}). These results suggest that the regulation of synaptic structural growth and tuning of synaptic strength have differential requirements for Mad signaling in motor neurons.

![**Loss of *nmo* does not lead to electrophysiological defects at the NMJ.** (A--F) Representative traces of EJCs and mEJCs from control (A), *Mad* mutant (B), or *nmo* mutant larvae (C) or from *Mad* mutant larvae presynaptically expressing UAS-Myc-Mad (D) or UAS-Myc-Mad^S25A^ (E) and from larvae overexpressing UAS-GFP-Nmo (F). In each panel, the top traces show 10 superimposed EJCs, and the bottom traces show the continuous recording of spontaneous mEJCs without nerve stimulation. The horizontal scale indicates time (40 ms for EJCs and 400 ms for mEJCs), and the vertical scale indicates current (8 nA for EJCs and 2 nA for mEJCs). (G) Graph of mEJC amplitude, EJC amplitude, quantal content (QC), and frequency of mEJCs for the following genotypes: BG380/+ (control), BG380/+;*Mad237/+* (*Mad/+*), BG380/+;*Mad^237/237^* (*Mad*), BG380/+;*Mad^237/237^;UAS-Myc-Mad* (Mad^WT^ rescue), BG380/+;*Mad^237/237^;UAS-Myc-Mad^S25A^/+* (Mad^S25A^ rescue), BG380/+;*nmo^DB24^/Df(3L)Exel6279* (*nmo*), BG380/+;*nmo^DB24^,* *UAS-GFP-Nmo/Df(3L)Exel6279* (Nmo rescue), BG380/+;*UAS-GFP-Nmo* (Nmo OE; *n* ≥ 10 for all genotypes; mean ± SEM; \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001). (H and I) Dorsal motor neurons in the ventral nerve cords of larvae expressing UAS-Myc-Mad alone or UAS-Myc-Mad together with UAS-GFP-Nmo are shown. Note the change in the distribution of Myc signal. (J) An NMJ at muscle 4 for the same genotype as in I is shown; Myc-Mad accumulates normally at the NMJ. OE, overexpression. Bars, 10 µm.](JCB_200809127_GS_Fig6){#fig6}

To further explore the action of Nmo on the regulation of neurotransmitter release, we conducted quantal analysis of larvae overexpressing Nmo ([Fig. 6, F and G](#fig6){ref-type="fig"}). Our analysis of synaptic structures showed no significant change in the number of synaptic boutons in response to Nmo overexpression ([Fig. 2 J](#fig2){ref-type="fig"}); however, unexpectedly, we found a drastic reduction in both EJCs and quantal content in response to Nmo overexpression in motor neurons (quantal content, 25.92 ± 4.7 for control vs. 14.38 ± 1.49 for UAS-GFP-Nmo; *n* = 12; P = 0.012; EJC, P = 0.007; [Fig. 6, F and G](#fig6){ref-type="fig"}). To learn about the relationship between this negative regulation and Nmo\'s interaction with Mad, we evaluated the distribution of Myc-Mad in motor neurons in response to Nmo gain-of-function. We found that in these larvae, Myc-Mad was present in both motor neuronal cell bodies and nuclei as well as at the NMJ ([Fig. 6, H--J](#fig6){ref-type="fig"}); however, the nuclear distribution of Myc-Mad appeared severely affected. Although Myc-Mad normally shows a strong concentration in the nuclei of motor neurons, when overexpressed together with GFP-Nmo, the Myc signal appeared evenly distributed in the cell body to a point that most nuclei were not easily detectable ([Fig. 6 I](#fig6){ref-type="fig"}). These results reveal a potential role for Nmo in the negative regulation of Mad, a role which was not revealed through our analysis of *nmo* loss-of-function, and highlight the ability of Nmo to regulate synaptic structural growth and neurotransmitter release differentially.

Discussion
==========

Our findings point to a model in which Nmo phosphorylation of Mad promotes its accumulation in the nuclei of motor neurons and thereby ensures effective BMP signaling at the NMJ. *nmo* mutant larvae show a significant aberration in the accumulation and/or distribution of p-Mad in motor neurons, with elevated levels of p-Mad at the NMJ and decreased levels of p-Mad in the nuclei of motor neurons. In addition, when Mad is mutated at its phosphorylation site for Nmo (Mad^S25A^), it shows an expression pattern that qualitatively resembles that of p-Mad in *nmo* mutants, with more accumulation at the NMJ and less accumulation in the nucleus compared with wild-type Mad. Consistent with the importance of this phosphorylation, Mad^S25A^ fails to rescue synaptic structural defects in Mad mutants effectively. These observations suggest that phosphorylation of Mad by Nmo most likely modulates Mad\'s function by regulating its distribution and accumulation in motor neurons. Based on our findings, it is tempting to conclude that the reduction in the number of NMJ synaptic boutons in *nmo* mutants is, to a large extent, caused by the failure of p-Mad to signal to the nucleus effectively. In support of this, we reveal a strong trans-heterozygous interaction between *nmo* and *Mad* and show that synaptic defects in *nmo* mutants can be partially rescued by overexpression of a constitutively active form of Tkv (Tkv-act). Although our current findings provide strong support for this model, we cannot rule out the possibility that Nmo is involved in other processes that contribute to the growth of synaptic boutons at the NMJ.

We find that, in contrast to its critical role in the regulation of synaptic structure, Nmo does not play an important role in the regulation of synaptic function; in the absence of *nmo*, quantal content remains at normal levels. Consistently, we find that the Mad^S25A^ transgene is capable of rescuing the severe electrophysiological defects of *Mad* mutants as efficiently as a wild-type Mad transgene. Previously, it has been suggested that structural growth and the homeostasis of neurotransmitter release at the NMJ have different requirements for BMP signaling ([@bib10]). Similarly, our findings highlight the differential requirements for the regulation of synaptic structure and synaptic strength via BMP signaling. Interestingly, although overexpression of Nmo in motor neurons does not influence synaptic structural growth, it does cause a significant reduction in neurotransmitter release. This observation is consistent with those made by [@bib37], showing an antagonistic effect of Nmo gain-of-function on Mad in the wing imaginal discs. Nevertheless, although this observation shows a potential for Nmo to act as a negative regulator of Mad, our findings argue against a significant negative regulatory role for Nmo in motor neurons under normal physiological conditions.

We propose that Nmo exerts its action primarily by modulating Mad\'s retrograde movement from the NMJ to the nucleus. Nmo has been implicated in the regulation of Mad nuclear export in heterologous cells ([@bib37]); however, we find no evidence for changes in Mad nuclear export as a consequence of loss of *nmo*. In contrast, we find that Nmo is required for accumulation of p-Mad in the nuclei of motor neurons. In the absence of *nmo*, p-Mad levels increase at the NMJ and decrease in the nuclei of motor neurons, suggesting that Nmo is required for normal translocation/trafficking of Mad from the NMJ to the nucleus.

Finally, we show that, consistent with previous findings ([@bib37]), overexpression of Nmo can reduce the proportion of Mad concentration in nuclei versus that in cell bodies of motor neurons. Based on the phenotypic consequences of *nmo* loss- and gain-of-function, it appears that normal growth of synaptic structures at the NMJ depends on continuous and efficient BMP signaling from the NMJ to the nuclei of motor neurons and is less sensitive to the residence time of Mad in the nucleus. However, it appears that regulation of neurotransmitter release is more sensitive to the residence time of Mad in the nucleus and less dependent on the continuous retrograde signaling from the NMJ. Our findings highlight the importance of Nmo phosphorylation of Mad at serine 25 in this process; however, a comprehensive understanding of the regulation of Mad trafficking and movement dynamics in different cellular compartments will require future studies.

Finally, an intriguing possibility would be the involvement of the Wg pathway in the regulation of Mad dynamics through Nmo. Nmo has been implicated in the Wg pathway during wing development and has been shown to be a transcriptional target of Wg ([@bib36]). As Wg has been shown to participate in the regulation of synaptic growth at the NMJ ([@bib21]), it would be tempting to envisage a role for Wg in the regulation of Nmo transcription in motor neurons and thus a link between the Wg and BMP pathways in the regulation of synaptic growth and function at the NMJ.

Materials and methods
=====================

Fly stocks
----------

Flies were cultured on standard medium at 25°C. The following fly stocks were used: UAS-GFP-Nmo (gift from R. Fiehler and T. Wolff, Washington University, St. Louis, MO; [@bib9]), UAS-Mito-GFP ([@bib7]), UAS-mCD8-GFP ([@bib14]), UAS-Tkv^Q199D^ (UAS-Tkv-act in this study; [@bib12]), *Df(3L)pbl-X1*, *Df(3L)pbl-NR*, *Df(3L)Exel6279* ([@bib22]), *Mad^K00237^* (*Mad^237^* in this study; [@bib2]), *Mad^6^* ([@bib27]), *nmo^P^* ([@bib5]), *nmo^DB24^* ([@bib36]), and *hiw^EMS^* ([@bib35]). Wild type refers to *w^1^* or *w^1118^* (Bloomington Stock Center). The neuronal Gal4 driver BG380 ([@bib4]) or OK6 and the muscle-specific Gal4 driver G14 ([@bib1]) were used.

*hiw* suppressor screen
-----------------------

To identify dominant suppressors of synaptic overgrowth in *hiw* mutants, we crossed *hiw^EMS^* recombined with Shaker-mCD8-GFP ([@bib35]; [@bib19]) females to chromosomal deficiency lines available on the left arm of the third chromosome from the Bloomington Deficiency kit (Bloomington Stock Center). We examined the hemizygous male *hiw^EMS^/Y*;;*Df/+* offsprings for reductions in NMJ boutons. We identified *Df(3L)pbl-X1* as a dominant suppressor and subsequently found that the smaller deficiency\'s *Df(3L)pbl-NR* and *Df(3L)Exel6279* also suppressed *hiw*. Among candidate genes uncovered by these deficiencies was *nmo*. We found that *nmo* mutants also suppressed *hiw* overgrowth; thus, we initiated our analysis of *nmo*.

Transgenic flies
----------------

For UAS-Myc-Mad, the full-length ORF of the *Mad* gene (FBgn0011648) was subcloned into a pUAST vector ([@bib3]) containing six N-terminal Myc repeats (pUAST-Myc). For UAS-Myc-Mad^S25A^, serine 25 was mutated to alanine by PCR using the primers 5′-TCACAGCGCCGGCGGTGAAGAAGCTGCTGGGCTGG-3′ and 5′-CCGGCGCTGTGAAGGAGAATAGCGAGCCCAGTGTG-3′, respectively, in combination with the XbaI-linked primer 5′-GGGGATCCTAATGGACACCGACGAT-3′ and the BamHI-linked primer 5′-GCTCTAGAGCTTAGGATACCGAACTAATTGCAT-3′. After an overlapping PCR, the assembled product was subcloned into pUAST-Myc. For UAS-GFP-Nmo^K69M^, site-directed mutagenesis was performed on UAS-GFP-Nmo wild type using the primers 5′-GGACGACGAGTGGCCTTGATGAAGCTGCCAAATGTGTTCC-3′ and 5′-GGAACACATTTGGCAGCTTCATCAAGGCCACTCGTCGTCC-3′. Transgenic Mad lines were generated according to standard protocols ([@bib28]), whereas the GFP-Nmo^K69M^ construct was injected by Best Gene, Inc.

Western blots and coimmunoprecipitation
---------------------------------------

Dissected third instar larvae were used for Western blotting as well as for immunoprecipitation experiments. Protein extraction was performed according to standard protocols. The following antibodies were used: mouse anti-GFP (1:500; Clontech Laboratories, Inc.), mouse anti--α-actin (1:2,000; Millipore), and mouse anti-Myc (1:200; Developmental Studies Hybridoma Bank). Peroxidase-conjugated secondary antibodies (1:5,000; Invitrogen) and ECL reagents (GE Healthcare) were used to detect the antigens. Densitometric analysis was performed using MetaMorph software (MDS Analytical Technologies). For immunoprecipitation experiments, protein from larvae overexpressing Myc-Mad was immunoprecipitated using an Anti--c-Myc Immunoprecipitation kit (Sigma-Aldrich). Immunoprecipitation was followed by Western blot analysis.

Immunochemistry
---------------

Wandering third instar larvae were dissected in cold HL3 ([@bib29]), fixed in 4% PFA (Sigma-Aldrich), incubated overnight with primary antibodies at 4°C, and incubated with fluorescence-conjugated secondary antibodies at room temperature. The following antibodies were used: rabbit polyclonal against GFP (1:500; A6455; Invitrogen), rabbit polyclonal against PS1 (1:500) and PS3 (1:200; p-Mad; provided by P. ten Dijke \[Leiden University, Leiden, Netherlands\] and C.H. Heldin \[Ludwig Institute for Cancer Research, Stockholm, Sweden\]; [@bib31]; [@bib30]), mouse monoclonal against Dlg (1:500; provided by C. Goodman, University of California, San Francisco, San Francisco, CA; [@bib23]), rabbit anti-Syt (1:2,000; provided by H. Bellen, Baylor College of Medicine, Houston, TX; [@bib16]), rabbit anti-Wnd (1:300; provided by A. DiAntonio \[Washington University, St. Louis, MO\] and C. Collins \[University of Michigan, Ann Arbor, MI\]; [@bib6]), mouse monoclonal against Fas2 (1:20; [@bib26]), and Cy5-conjugated goat against HRP (1:250; Jackson ImmunoResearch Laboratories). Antibodies obtained from the Developmental Studies Hybridoma Bank were mouse monoclonal against Myc (1:20; 9E10) and mouse monoclonal against β-gal (1:500; 40-1A). Secondary antibodies used were Alexa Fluor 488--conjugated goat against rabbit (1:500; Invitrogen) and Cy3-conjugated goat against mouse (1:500; GE Healthcare). DAPI was used at 1× (Sigma-Aldrich) together with the secondary antibodies. Samples were mounted in Vectashield (Vector Laboratories).

Confocal imaging and bouton counts
----------------------------------

Synapses and ventral nerve cords were imaged using a ConfoCor LSM 510 META on an inverted microscope (Axiovert 200M; Carl Zeiss, Inc.). Settings were optimized for detection without saturating the signal. Images were obtained at room temperature using a Plan-Apochromat 63× NA 1.4 immersion oil objective lens (Carl Zeiss, Inc.) and Immersol oil 518N (Carl Zeiss, Inc.). Images were cropped using Photoshop CS2 (Adobe).

Synaptic boutons were counted as previously described ([@bib26]) using the muscles of segment 3, with the following modifications: NMJs were costained with anti-Dlg and anti-HRP antibodies, and the counts were performed with a 63× NA 1.4 oil immersion objective using an epifluorescence microscope (Imager Z1; Carl Zeiss, Inc.).

Fluorescence quantification
---------------------------

Maximum projection images of NMJs and ventral nerve cords were generated from stacked confocal images (0.32 and 0.5 µm thickness, respectively). To compare intensities of p-Mad puncta at NMJs, synaptic boutons were manually traced using Fas2 staining. p-Mad immunofluorescence levels were quantified by measuring the intensity using the LSM5 META MK4 software (Carl Zeiss, Inc.). The peak signal intensities of p-Mad puncta, from ∼150 boutons per genotype, were then plotted and compared across genotypes. Alternatively, we quantified p-Mad at the NMJ by measuring the integrated fluorescence signal associated with p-Mad and normalizing it to the Fas2 signal at the same NMJ using MetaMorph software.

For Myc quantification at the NMJ, the integrated fluorescence signal per synaptic area was measured using the HRP signal to delineate synaptic boutons. To assess the fluorescence signals associated with p-Mad, β-gal, and Myc in the nuclei of motor neurons, a standard area of 25 µm^2^ per motor neuron nucleus was used for larval segments A5, A6, and A7. Signals were quantified with MetaMorph software.

To generate the relative fluorescence intensity between the NMJ and motor neuronal nuclei for Myc-Mad versus Myc-Mad^S25A^, we divided the mean intensity per area, measured for at least 50 boutons, by the mean intensity per area for at least 30 motor neurons for each larva. To quantify Syt accumulation in axons, maximum projections of larval axons stained with anti-Syt were generated from stacked confocal images. MetaMorph software was used to determine the number of large Syt puncta (≥0.75 µm in diameter) present in each projection.

Electrophysiology
-----------------

Wandering third instar larvae were dissected in cold HL3 solution according to standard protocol ([@bib29]). A standard two-electrode voltage-clamp technique was used to measure mEJC and EJC at muscle 6 in segment A3 in wandering third instar larvae using an amplifier (AxoClamp 2B; MDS Analytical Technologies). All recordings were performed at room temperature in HL3 with 0.5 mM external Ca^2+^, and muscles were held at −80 mV. The holding current was \<3 nA.

Statistical analysis
--------------------

Data are presented as mean values ± SEM (*n* = number of NMJs unless otherwise indicated), and Student\'s *t* tests were used to calculate statistical significance (\*, P \< 0.05; \*\*, P \< 0.01; and \*\*\*, P \< 0.001).

Online supplemental material
----------------------------

Fig. S1 shows dominant suppression of *hiw* mutants by loss of one copy of *nmo* as well as staining for Wnd in the ventral nerve cord. Fig. S2 shows accumulation of Mito-GFP or Syt in axons. Fig. S3 shows a Western blot for Myc-Mad and Myc-Mad^S25A^. Fig. S4 shows expression of Nmo^KD^ and its failure to rescue p-Mad abnormalities in *nmo* mutants. Fig. S5 shows the partial rescue of *nmo* by overexpression of Tkv-act. Onine supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200809127/DC1>.
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